In H1 2021, Lonza continued its strong performance with 14.7%1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19 Continued focus on growth CAPEX investments, supported by strong business pipeline Expanded collaborations to support COVID-19 programs including Moderna Divestment of Specialty Ingredients business completed on 1 July 2021 Path forward for a […]
continue reading